Klingman & Associates LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 40.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,930 shares of the company’s stock after selling 10,777 shares during the quarter. Johnson & Johnson comprises about 0.5% of Klingman & Associates LLC’s investment portfolio, making the stock its 27th largest position. Klingman & Associates LLC’s holdings in Johnson & Johnson were worth $2,226,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Linscomb & Williams Inc. lifted its stake in Johnson & Johnson by 1.9% in the third quarter. Linscomb & Williams Inc. now owns 62,922 shares of the company’s stock valued at $8,181,000 after buying an additional 1,153 shares during the period. Cable Hill Partners LLC lifted its stake in Johnson & Johnson by 21.5% in the third quarter. Cable Hill Partners LLC now owns 4,876 shares of the company’s stock valued at $634,000 after buying an additional 862 shares during the period. YorkBridge Wealth Partners LLC lifted its stake in Johnson & Johnson by 2.9% in the third quarter. YorkBridge Wealth Partners LLC now owns 32,966 shares of the company’s stock valued at $4,286,000 after buying an additional 936 shares during the period. Bourgeon Capital Management LLC lifted its stake in Johnson & Johnson by 9.3% in the third quarter. Bourgeon Capital Management LLC now owns 6,178 shares of the company’s stock valued at $803,000 after buying an additional 528 shares during the period. Finally, Conning Inc. lifted its stake in Johnson & Johnson by 2.1% in the third quarter. Conning Inc. now owns 358,664 shares of the company’s stock valued at $46,630,000 after buying an additional 7,245 shares during the period. 67.40% of the stock is currently owned by institutional investors and hedge funds.
Shares of Johnson & Johnson opened at $126.06 on Tuesday, MarketBeat Ratings reports. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $341.37 billion, a price-to-earnings ratio of 16.90, a price-to-earnings-growth ratio of 1.95 and a beta of 0.74. Johnson & Johnson has a 1 year low of $125.86 and a 1 year high of $127.60.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. Johnson & Johnson’s quarterly revenue was up 12.6% on a year-over-year basis. During the same period last year, the company earned $1.83 earnings per share. research analysts predict that Johnson & Johnson will post 8.13 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be issued a dividend of $0.90 per share. The ex-dividend date is Friday, May 25th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.03%.
Several research firms have weighed in on JNJ. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. BTIG Research reissued a “sell” rating and issued a $110.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Stifel Nicolaus increased their target price on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a research note on Tuesday, January 23rd. Finally, Citigroup cut their target price on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 27th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $142.23.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.22% of the stock is currently owned by company insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.